New Analyst Forecast: $ELVN Given $52.0 Price Target

ELVN has seen recent analyst activity with Robert W. Baird setting a price target of $52.0, above the median target of $45.5 from two analysts in the last six months. Over the same period, company insiders have sold shares 41 times with no purchases, while hedge fund activity in Q1 2025 was mixed, with some firms like Commodore Capital and Blackstone increasing their positions, while others such as Citadel Advisors and 5AM Venture Management reduced theirs.

Analysis

Enliven Therapeutics (ELVN) has received a new price target of $52.0 from Colleen Kusy at Robert W. Baird, set on June 16, 2025, which is notably higher than the median target of $45.5 from two analysts over the past six months; the other recent target was $39.0 from H.C. Wainwright on March 21, 2025. This analyst optimism contrasts sharply with significant insider selling activity: over the last six months, insiders executed 41 sales and zero purchases. Key executives, including CEO Samuel Kintz (8 sales, 50,000 shares for an estimated $1,002,928), COO Anish Patel (14 sales, 61,702 shares for an estimated $1,353,432), CSO Joseph Lyssikatos (7 sales, 37,500 shares for an estimated $720,084), and CFO Benjamin Hohl (12 sales, 26,500 shares for an estimated $551,354), have all been net sellers, contributing to a strongly negative sentiment score of -0.7 for the ticker. Institutional ownership presents a mixed picture for Q1 2025, with 64 investors adding to their positions and 53 decreasing. Notable increases include Commodore Capital LP adding 470,000 shares (+11.2%) and Blackstone Inc. adding 388,984 shares (+104.2%). Conversely, Citadel Advisors LLC reduced its stake by 615,394 shares (-35.4%), 5AM Venture Management, LLC cut its position by 307,288 shares (-18.9%), and Adage Capital Partners GP, L.L.C. removed 200,000 shares (-30.8%), while Cutter Capital Management, LP completely exited its position of 207,896 shares in Q4 2024.

Key Decisions for Investors

• Investors should view the recent analyst price target of $52.0 for ELVN with caution due to the contradictory signal of 41 insider sales and zero purchases over the past six months, amounting to significant divestment by key executives.
• The mixed institutional activity, with 64 funds adding shares and 53 decreasing in Q1 2025, including large reductions by firms like Citadel Advisors and complete exits like Cutter Capital Management in Q4 2024, warrants close monitoring of subsequent filings to discern a clearer institutional consensus.
• Given the strongly negative sentiment (-0.7 for ELVN) and substantial insider selling, investors should critically evaluate if the potential upside suggested by analyst targets adequately compensates for the risks indicated by these internal and market signals before committing capital.